Malaysia
Search
Sign In
Change Password
Points
Sign Out
Cardiology
Top Medical News
A systematic implementation of evidence-based interventions helps improve smoking cessation in postmyocardial infarction (MI) patients, a recent study has found.
About 10 percent of patients with the coronavirus disease 2019 (COVID-19) will suffer from upper extremity deep vein thrombosis despite adequate prophylaxis, a recent study has found.
Moderate to severe obstructive sleep apnoea (OSA) shows an independent association with the interarm systolic blood pressure (SBP) difference (IAD), but not with interankle SBP difference (IAND) and ankle-brachial index (ABI), suggests a study.
While tranexamic acid improves blood control after coronary artery bypass graft (CABG) surgery, it increases the risk of perioperative myocardial infarction, a recent study has found.
Women with pregnancy-induced hypertension are at increased risk of developing arrhythmia, but not lethal arrhythmias, within 1 year after delivery, a study reports.
Increased levels of dietary sodium (Na) intake and load (Na-L) appear to cause arterial stiffness, a preclinical measure of cardiovascular disease (CVD), in children and young adults, according to a study.
The interaction of hypertension and total plasma homocysteine (tHcy) levels contributes to the risk of all-cause mortality among middle-aged and older adults, a US study has found. In addition, hypertension may boost the ability of elevated tHcy to aggravate this risk.
Special Reports
HFpEF represents a significant unmet need in CV medicine due to
its prevalence, poor prognosis, and the absence of clinically proven
therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous
clinical benefits in cardiorenal outcomes of empagliflozin in adults with
HFpEF, which were consistent with the observations in adults with HFmrEF/
HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR
trials establish empagliflozin’s efficacy in heart failure regardless of
ejection fraction – and if approved, empagliflozin would become the first and
only clinically proven therapy to improve outcomes for the full spectrum of
the disease. Therefore, empagliflozin offers a new hope for people living
with heart failure.
Heart failure with preserved
ejection fraction (HFpEF) represents a significant unmet medical need. The
EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on
cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the
hotline session of the 2021 ESC Virtual Congress, the main results of the
EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal
investigator of the study, and heart failure specialist at Charité Berlin,
Germany.
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]
Edoxaban 30 mg and 60 mg FC tab
Perindopril arginine 3.5 mg,
Amlodipine besilate 2.5 mg tab
Amlodipine besilate 2.5 mg tab
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Conference Reports
Daily coffee intake is tied to increased physical activity and incidence of premature ventricular contractions (PVCs) but fewer episodes of supraventricular tachycardia (SVT) and less nighttime sleep in the CRAVE* trial.
The choice of oral anticoagulant does not appear to influence the outcome in terms of preserving cognitive function in older patients with atrial fibrillation (AF), the GIRAF* study has shown.
Undergoing CABG* within 2 to 3 days after stopping the antiplatelet ticagrelor does not increase the risk of severe/massive bleeding compared with delaying surgery until 5 to 7 days of ticagrelor discontinuation in patients with ACS**, according to the RAPID CABG *** study presented at AHA 2021.
Treatment with evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C) levels in adolescents and adults with homozygous familial hypercholesterolaemia (FH), according to a study presented at AHA 2021.
Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.
The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.
Multimedia
